Adding atezolizumab to FOLFOX chemotherapy after surgery boosts disease-free survival in patients with surgically resected mismatch repair deficient …
Adding atezolizumab to FOLFOX chemotherapy after surgery boosts disease-free survival in patients with surgically resected mismatch repair deficient …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
A large phase III study known as SERENA-6 is attracting wide attention for challenging the way resistance is …
In the UK DANTE trial stopping immunotherapy at 12 months produces disease control rates comparable to two-year treatment …
U.S. regulators expand treatment options in prostate cancer as biotech innovators TRexBio and Spinogenix push forward with immune …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
Landmark ATOMIC trial shows combining immunotherapy and chemo improves outcomes for colon cancer patients with mismatch-repair deficiency
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
Results from the Sunrise-1 trial suggest a new option for patients with second-line papillary non-muscle invasive bladder cancer
New data from India suggest that Hillchol, an oral cholera vaccine by Bharat Biotech, is safe, effective and …
Already a subscriber? Log in